US FDA grants breakthrough therapy designation for Roche's investigational medicine ACE910 for people with haemophilia A with factor VIII inhibitors

Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ACE910 (RG6013, RO5534262) for the prophylactic treatment of people who are 12 years or older with haemophilia A with factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news